


**Understand. Act.** 



### Outperformance relative to benchmark



As at 30/11/2014	NAV(debt @ par)	NAV (debt @ fair value)	Benchmark
1 Year	3.8	3.6	6.5
3 Years	38.3	43.4	36.3
5 Years	45.9	46.5	45.9


For period: 30/11/2014 – 27/02/2015	
Brunner Capital NAV	+4.9%
Brunner NAV Debt at Fair	+5.3%
Brunner BM Price Index	+3.5%




### Consistently growing dividend

# 43 years' uninterrupted dividend growth

- Pays out quarterly dividends
- One of highest yielding trusts in its sector of 2.7%
- Strong revenue reserves = 1.6x total dividend for 2014
- 2/3rds dividend come from UK stocks
- Board is minded to grow the dividend in excess of inflation








Top Contributors	Active Contribution
Abbvie	0.6%
Allergan	0.5%
Microsoft	0.4%
Celgene	0.4%
Shire	0.4%
Tyman	0.3%
Standard Chartered (not owned)	0.3%
Intercontinental Hotels	0.3%
UnitedHealth	0.3%
Astellas Pharma	0.3%





Worst Contributors	Active Contribution
Tesco	-0.4%
Mothercare	-0.4%
Aztrazeneca (not owned)	-0.4%
Better Capital	-0.3%
Adidas	-0.3%
Balfour Beatty	-0.3%
UBM	-0.3%
BG	-0.3%
Tullett Prebon	-0.2%
Spectris	-0.2%





### **Purchases**

Consumer/ Healthcare	Industrials/ Technology	Financials
William Hill PLC	United Internet	Ashmore Group PLC
Nielsen	Weir Group	Better Capital
	Intertek	Accenture
	Sthree	
	Rolls Royce	
	EOG Resources	
	Monsanto	






#### Sales

Consumer/ Healthcare	Industrials/ Technology	Financials
Henkel	Suncor Energy	Vienna Insurance
Reed Elsevier	Inmarsat	Fubon Financial
Intercontinental Hotels	Toyota Motor	Crown Castle
Genting Singapore	F5 Networks	
Starbucks	Jardine Matheson	
CBS		





Global recovery on track

Central Bank liquidity supportive

Volatility may increase

Equity valuations fair


Quality, growth and dividends matter



### Investment themes










### Investment themes Health Care

- 1. Innovation & research key
- 2. Biotech R&D more efficient
- 3. Multi-year patent protection = "winner take all"
- Themes:
- Oncology: GSK, Roche, Celgene, Astellas
- Immunology: AbbVie, UCB
- HCV: AbbVie
- Med Tech: Smith & Nephew, Fresenius SE

### Immunotherapy could accelerate the decline in cancer mortality rates






### Investment themes Media and Technology

- 1. Mobile/e-commerce everything
- 2. Cloud = deflation
- 3. Internet of Things (IOT)

#### Themes:

- Online Advertising & Transactions: Google, Visa, Cielo, Nielsen
- Online Travel: Priceline Group, Amadeus IT
- Cloud/Business Transformation: Microsoft, Accenture, Xchanging
- IOT: Microchip
- Social Media: Google

### Mobile advertising is growing rapidly




- Mobile Advertising (in S billions)
- % of Total Online Ads




### Investment themes Industrials

- 1. Secular growth drivers: Infrastructure, urbanisation, EM
- 2. Oligopolies, niche markets
- 3. Aftermarket = pricing power
- 4. Internet of Things
- Themes:
- Automation: Spectris, AMETEK, Flowserve, SMC
- Aerospace: Rolls-Royce
- Energy efficiency: Schneider Electric
- Agriculture: Monsanto

### **Computing Growth Drivers 1960-2030e**







A bottom-up global growth stock picking trust

Performance ahead of benchmark over 3, 5 and 10 years

One of the highest yielding trusts in its sector with over 40 years consecutive dividend growth

Virtual 24 hour office with a robust investment process

Low management fee of 0.45% p.a.



### Portfolio managers

#### **Biographies**



#### Lucy Macdonald, ASIP (CFA UK)

CIO, Global Equities

Lucy joined the team in October 2001. She heads the Global Equity Fund Management team, which is responsible for global mandates from clients around the world with currently over £4bn of assets under management. She was instrumental in launching the Global High Alpha product in 2003, now representing over £3bn of global equity assets, which she also manages. Lucy is a member of the AllianzGl Global Policy Council, which is responsible for setting company-wide macro-economic and strategic policy. Prior to AllianzGl, Lucy spent 16 years, latterly as a Director and Senior Portfolio Manager, at Baring Asset Management managing High Alpha funds. Lucy graduated from Bristol University in 1984, and is an Associate of the Society of Investment Professionals (ASIP). She was made a Managing Director of AllianzGl in December 2007.



Jeremy Thomas, ASIP (CFA UK)

Portfolio Manager, Global Equities

Jeremy joined in 2004 and moved to the Global Equity Fund Management Team in October 2012. He is a member of the European Equity Core portfolio management team and co-manages the Brunner Investment Trust which invests in companies globally. Prior to that he was a portfolio manager on the UK equity team and appointed CIO UK Equities in 2010. Jeremy was also a director in the UK Equity Portfolio Management Team at ISIS Asset Management, where he was responsible for stock selection and portfolio construction for UK pension funds. He also set sector strategy and had specific sector research responsibilities. Between 1996-2002 he was an associate director at Schroder Investment Management, where he managed the Schroder Portfolio Fund. He graduated from Mansfield College, Oxford University with an Honours degree in Philosophy, Politics and Economics and subsequently joined the British Army where he attained the rank of Captain. Jeremy has 18 years of industry experience and holds the AIMR (Association for Investment Management and Research) qualification.





### Disclaimer

This is no recommendation or solicitation to buy or sell any particular security. Any security mentioned above will not necessarily be comprised in the portfolio by the time this document is disclosed or at any other subsequent date. Investment trusts are quoted companies listed on the London Stock Exchange. Their share prices are determined by factors including the balance of supply and demand in the market, which means that the shares may trade below (at a discount to) or above (at a premium to) the underlying net asset value.

The Trust seeks to enhance returns for its shareholders through gearing in the form of long-term debentures. Gearing can boost the Trust's returns when investments perform well, though losses can be magnified when investments lose value. You should be aware that this Trust may be subject to sudden and large falls in value and you could suffer substantial capital loss.

A trust's Net Asset Value (NAV) is calculated as available shareholders' funds divided by the number of shares in issue, with shareholders' funds taken to be the net value of all the company's assets after deducting liabilities. In line with current industry best practice NAVs are now shown that take into account the 'fair value' of debt. This means NAVs are calculated after allowing for the valuation of debt at fair value or current market price, rather than at final repayment value. NAVs with debt at market value provide a more realistic impact of the cost of debt, and thus a more realistic discount. It is the capital NAV that is shown, which excludes any income.

Investing involves risk. The value of an investment and the income from it may fall as well as rise and investors may not get back the full amount invested. The views and opinions expressed herein, which are subject to change without notice, are those of the issuer and/or its affiliated companies at the time of publication. The data used is derived from various sources, and assumed to be correct and reliable, but it has not been independently verified; its accuracy or completeness is not guaranteed and no liability is assumed for any direct or consequential losses arising from its use, unless caused by gross negligence or wilful misconduct. The conditions of any underlying offer or contract that may have been, or will be, made or concluded, shall prevail. Past performance is not a reliable indicator of future results.

The Trust is a UK public limited company traded openly on the stock market. You can purchase shares through a stock broker. Shares in the Trust can be held within an ISA and/or savings scheme and a number of providers offer this facility. A list of suppliers is available on our website.

This is a marketing communication issued by Allianz Global Investors GmbH, an investment company with limited liability, incorporated in Germany, with its registered office at Bockenheimer Landstrasse 42-44, D-60323 Frankfurt/Main, registered with the local court Frankfurt/Main under HRB 9340, authorised by Bundesanstalt für Finanzdienstleistungsaufsicht (www.bafin.de). Allianz Global Investors GmbH has established a branch in the United Kingdom, Allianz Global Investors GmbH, UK branch, which is subject to limited regulation by the Financial Conduct Authority (www.fca.org.uk). Details about the extent of our regulation by the Financial Conduct Authority are available from us on request.

All data source Allianz Global Investors as at 31.01.15 unless otherwise stated. Allianz Global Investors GmbH, UK Branch, 199 Bishopsgate, London EC2M 3TY



**Understand. Act.** 



**Understand. Act.** 



#### Resolution 1:

To receive and adopt the Annual Financial Report

For	Discretion	Against	Withheld
16,210,426	9,816	100,096	6,559



### **Resolution 2:**

To declare a final dividend

For	Discretion	Against	Withheld
16,314,023	9,816	0	3,058



#### **Resolution 3:**

To re-elect Keith Percy as a Director

For	Discretion	Against	Withheld
15,809,553	9,816	293,394	214,134



### Resolution 4:

To re-elect Vivian Bazalgette as a Director

For	Discretion	Against	Withheld
15,829,415	9,816	272,289	215,377



#### **Resolution 5:**

To approve the Directors' Remuneration Implementation Report

For	Discretion	Against	Withheld
15,589,676	9,816	480,329	247,076



#### **Resolution 6:**

To re-appoint Deloitte LLP as Auditor

For	Discretion	Against	Withheld
15,734,721	9,816	142,299	440,061



#### Resolution 7:

To authorise the Directors to determine the remuneration of the Auditor

For	Discretion	Against	Withheld
16,034,812	9,816	112,288	169,981



#### **Resolution 8:**

To renew the Directors' authority to allot Ordinary Shares

For	Discretion	Against	Withheld
16,115,796	29,955	163,557	17,589



### Resolution 9:

To disapply pre-emption rights

For	Discretion	Against	Withheld
15,814,487	29,955	334,254	148,201



#### Resolution 10:

To authorise the Company to make market purchases of Ordinary Shares

For	Discretion	Against	Withheld
16,063,217	29,955	231,968	1,757



#### Resolution 11:

To adopt new Articles of Association

For	Discretion	Against	Withheld
15,717,475	30,264	104,027	475,131



**Understand. Act.**